Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease
BUZZ-Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease ** Shares of gene therapy developer Lexeo Therapeutics LXEO.O rise 14% to $4.98
** Co says it finalized design of a key study for LX2006, a gene therapy for heart disease linked to Friedreich ataxia, a rare inherited disorder that damages nerves and the heart
** Says study will test if a one-time gene therapy can reduce thickened heart muscle, using MRI scans to track changes
** LXEO says 26 patients aged 16 plus to be enrolled; half get treatment, half untreated controls who may switch after six months
** Says U.S. FDA advised against using a placebo procedure in the trial design
** Adds patient enrollment to start by end-June; aims for approval filing in 2028 with data due in second half of 2027
** Including session's move, stock down ~50% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease